{"protocolSection": {"identificationModule": {"nctId": "NCT01415921", "orgStudyIdInfo": {"id": "10-02167"}, "secondaryIdInfos": [{"id": "10-02167", "type": "OTHER", "domain": "NYU IRB"}, {"id": "1R01HL103988", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/1R01HL103988"}], "organization": {"fullName": "NYU Langone Health", "class": "OTHER"}, "briefTitle": "Safety Study of Pyridostigmine in Heart Failure", "officialTitle": "Augmentation of Parasympathetic Signaling With Pyridostigmine in Heart Failure", "acronym": "APP-HF"}, "statusModule": {"statusVerifiedDate": "2017-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-10"}, "primaryCompletionDateStruct": {"date": "2015-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-08-10", "studyFirstSubmitQcDate": "2011-08-11", "studyFirstPostDateStruct": {"date": "2011-08-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-05-20", "resultsFirstSubmitQcDate": "2016-08-31", "resultsFirstPostDateStruct": {"date": "2016-10-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-07-27", "lastUpdatePostDateStruct": {"date": "2017-07-31", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "NYU Langone Health", "class": "OTHER"}, "collaborators": [{"name": "Nathan Kline Institute for Psychiatric Research", "class": "OTHER"}, {"name": "Oklahoma State University", "class": "OTHER"}, {"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Heart failure, a common heart disease affecting nearly 6 million Americans, is associated with high rates of hospitalization and death. Abnormalities in the autonomic nervous system are thought to play an important role in the progression of heart failure. This proposal aims to determine whether novel application of pyridostigmine, a drug currently approved by the FDA only for the treatment of neuromuscular disease, can improve autonomic nervous system function in heart failure patients.", "detailedDescription": "Autonomic dysregulation of the cardiovascular system, characterized by heightened sympathetic activity and withdrawal of parasympathetic activity promotes progression of heart failure. Pharmacological blockade of sympathetic overactivity is associated with reduced mortality risk, but there are few data on pharmacologic augmentation of parasympathetic withdrawal. Acetylcholinesterase inhibitors augment parasympathetic neurotransmission by blocking the enzymatic breakdown of acetylcholine at cholinergic receptor sites. Pyridostigmine is a short-acting, reversible acetylcholinesterase inhibitor approved by the FDA for the treatment of myasthenia gravis. Investigators propose a Phase II prospective randomized, double-blind trial to compare 12 weeks of treatment with ascending doses of pyridostigmine (15, 30, and 60 mg every 8 hours) vs. matching placebo in 60 patients with symptomatic chronic heart failure associated with left ventricular systolic dysfunction."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["heart failure", "autonomic function", "sympathovagal balance", "cholinesterase inhibitors", "pharmacology"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 33, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Pyridostigmine Bromide", "type": "EXPERIMENTAL", "description": "Forced titration protocol 15-60 mg every 8 hours as tolerated", "interventionNames": ["Drug: Pyridostigmine Bromide"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Matching placebo forced titration 15-60 mg as tolerated", "interventionNames": ["Drug: Pyridostigmine Bromide"]}], "interventions": [{"type": "DRUG", "name": "Pyridostigmine Bromide", "description": "15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.", "armGroupLabels": ["Placebo", "Pyridostigmine Bromide"], "otherNames": ["Mestinon"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Baseline Heart Rate Recovery", "description": "Change in peak HR at end of exercise to 1 minute post-exercise (beats per minute)", "timeFrame": "Baseline"}, {"measure": "Post Exercise Heart Rate Recovery", "description": "Change in heart rate from peak exercise to 1 minute post-exercise (beats per minute)", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age 21-75 years\n* Symptomatic NYHA Class II-III heart failure \\>6 months\n* Left ventricular ejection fraction \\<35%\n* Previous implantation of implantable cardiovertor defibrillator or pacemaker\n* Guideline-recommended heart failure treatment for \\> 3 months\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Contraindications to cholinergic stimulation\n* Heart failure primarily attributable to genetic, valvular, infiltrative diseases\n* Persistent atrial fibrillation\n* Sick sinus syndrome\n* Pacemaker dependency during exercise\n* Severe chronotropic incompetence with peak exercise heart rate \\< 100 min-1\n* Severe exercise intolerance (unable to complete first stage of Bruce Protocol)\n* Coronary or cerebral atherothrombotic events within the past year\n* Hospitalization of emergency room visit for heart failure within last 3 months\n* ICD shock in last 6 months\n* Diabetes mellitus with peripheral neuropathy\n* Autonomic or peripheral neuropathy of any cause\n* Systolic blood pressure \\<90 or \\>160 mmHg\n* Resting heart rate \\<60 or \\>100 min-1\n* Serum sodium \\< 132 mmol/L\n* Serum creatinine \\>2.5 mg/dl\n* Liver function tests \\>3 times upper limit of normal\n* Severe anemia (Hemoglobin \\<10 gm/dl)\n* FEV1.0 \\< 60% of predicted or FEV1.0/FVC ratio \\<70%\n* PR interval \\>240 msec or second or third degree heart block on electrocardiogram\n* Exercise limited primarily by angina or non-cardiac co-morbid condition\n* Pregnant or breast-feeding women\n* Current treatment with medications known to interact with pyridostigmine\n* Known intolerance of oral preparations containing bromides\n* Any condition (e.g., psychiatric illness or active substance abuse) or situation that, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's ability to adhere with study procedures.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Stuart D Katz, MD", "affiliation": "NYU Langone Health", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "New York University Langone Medical Center", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}]}, "referencesModule": {"references": [{"pmid": "12860856", "type": "BACKGROUND", "citation": "Androne AS, Hryniewicz K, Goldsmith R, Arwady A, Katz SD. Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. Heart. 2003 Aug;89(8):854-8. doi: 10.1136/heart.89.8.854."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Admissions logs and other existing electronic hospital information systems", "groups": [{"id": "FG000", "title": "Pyridostigmine Bromide", "description": "Forced titration protocol 15-60 mg every 8 hours as tolerated\n\nPyridostigmine Bromide: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue."}, {"id": "FG001", "title": "Placebo", "description": "Matching placebo forced titration 15-60 mg as tolerated\n\nPyridostigmine Bromide: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "17"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Pyridostigmine Bromide", "description": "Forced titration protocol 15-60 mg every 8 hours as tolerated\n\nPyridostigmine Bromide: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue."}, {"id": "BG001", "title": "Placebo", "description": "Matching placebo forced titration 15-60 mg as tolerated\n\nPyridostigmine Bromide: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "33"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "29"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "29"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "9"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "17"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "33"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Baseline Heart Rate Recovery", "description": "Change in peak HR at end of exercise to 1 minute post-exercise (beats per minute)", "populationDescription": "Heart rate recovery is also measured as beats/min (peak HR at end of exercise - HR 1 min post exercise = HRR).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats per minute", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Pyridostigmine Bromide", "description": "Forced titration protocol 15-60 mg every 8 hours as tolerated\n\nPyridostigmine Bromide: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo forced titration 15-60 mg as tolerated\n\nPyridostigmine Bromide: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.5", "spread": "12.8"}, {"groupId": "OG001", "value": "30.4", "spread": "14.8"}]}]}]}, {"type": "PRIMARY", "title": "Post Exercise Heart Rate Recovery", "description": "Change in heart rate from peak exercise to 1 minute post-exercise (beats per minute)", "populationDescription": "Heart rate recovery is also measured as beats/min (peak HR at end of exercise - HR 1 min post exercise = HRR).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats per minute", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Pyridostigmine Bromide", "description": "Forced titration protocol 15-60 mg every 8 hours as tolerated\n\nPyridostigmine Bromide: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue."}, {"id": "OG001", "title": "Placebo", "description": "Matching placebo forced titration 15-60 mg as tolerated\n\nPyridostigmine Bromide: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "38.5", "spread": "12.2"}, {"groupId": "OG001", "value": "34.9", "spread": "16.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Pyridostigmine Bromide", "description": "Forced titration protocol 15-60 mg every 8 hours as tolerated\n\nPyridostigmine Bromide: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.", "seriousNumAffected": 2, "seriousNumAtRisk": 16, "otherNumAffected": 11, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Placebo", "description": "Matching placebo forced titration 15-60 mg as tolerated\n\nPyridostigmine Bromide: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.", "seriousNumAffected": 3, "seriousNumAtRisk": 17, "otherNumAffected": 10, "otherNumAtRisk": 17}], "seriousEvents": [{"term": "Decompensated Heart Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Elective Stent Placement", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Abdominal Paim", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Fever", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Ventricular Malposition of an ICD Lead", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}], "otherEvents": [{"term": "Leukocytosis", "organSystem": "Blood and lymphatic system disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Chest Pain", "organSystem": "Cardiac disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Blurred vision of right eye", "organSystem": "Eye disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Loose Stools", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 17}]}, {"term": "Bloating", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Black Stool", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Flu like symptoms", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Fatigue", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Ankle sprain", "organSystem": "Injury, poisoning and procedural complications", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Pacemaker AMS", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Inadequate ICD shock", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Ventricular pacing", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Supraventicular tachycardia reported on ICD", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Total Bilirubin Increased", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Elevated Alkaline Phosphatase", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Elevated hepatic enzymes", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Thrombocitopenia", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Percent Eosinophils Increased", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "PMT (Pacemaker Tachycardia)", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Pain in lower extremities", "organSystem": "Musculoskeletal and connective tissue disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Tendinitis", "organSystem": "Musculoskeletal and connective tissue disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Plantar Fasciitis", "organSystem": "Musculoskeletal and connective tissue disorders", "notes": "Plantar Fasciitis", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Gout", "organSystem": "Musculoskeletal and connective tissue disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "notes": "Dizziness", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Urinary Incontinence", "organSystem": "Renal and urinary disorders", "notes": "Urinary Incontinence", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Sore throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Sore throat", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "Sweating", "organSystem": "Skin and subcutaneous tissue disorders", "notes": "Sweating", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "notes": "Rash", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Low heart rate", "organSystem": "Vascular disorders", "notes": "Low heart rate", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "notes": "Hypertension", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 17}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Stuart Katz, MD", "organization": "New York University School of Medicine", "email": "stuart.katz@nyumc.org", "phone": "212-263-3946"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001965", "term": "Bromides"}, {"id": "D000011729", "term": "Pyridostigmine Bromide"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000002800", "term": "Cholinesterase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M5241", "name": "Bromides", "asFound": "Root", "relevance": "HIGH"}, {"id": "M14582", "name": "Pyridostigmine Bromide", "asFound": "Sleep patterns", "relevance": "HIGH"}, {"id": "M6040", "name": "Cholinesterase Inhibitors", "relevance": "LOW"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}